XML 56 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Fair value of financial instruments and marketable securities - Narrative (Details)
1 Months Ended 3 Months Ended
Feb. 28, 2021
USD ($)
fund
$ / shares
Jan. 31, 2020
USD ($)
$ / shares
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Apr. 29, 2020
Sep. 30, 2019
USD ($)
$ / shares
May 31, 2019
USD ($)
$ / shares
Aug. 31, 2015
USD ($)
$ / shares
Financial assets and liabilities measured at fair value on recurring basis                  
Write downs of available for sale debt securities     $ 0            
Realized gain (loss) from sale of marketable securities     700,000 $ 0          
Increase in allowance for credit losses     0 0          
Unrealized gain on convertible note     7,900,000 2,800,000          
Unrealized gain (loss) on ClearPoint Equity Investment     6,764,000 (1,574,000)          
Marketable securities - equity investments     27,400,000   $ 20,500,000        
Purchase of convertible debt investment   $ 10,000,000.0   10,000,000          
Conversion price per share (in dollars per share) | $ / shares   $ 6.00              
Debt instrument, convertible, period   5 years              
Fair value of convertible debt     37,100,000   29,300,000        
Purchase of marketable securities - equity investments $ 200,000,000.0   200,000,000            
Number of mutual funds invested in | fund 2                
Unrealized (gain) loss on marketable securities - equity investments     302,000            
Transfers of assets measured between Level 1, Level 2, and Level 3     0   0        
Operating Expenses     216,090,000 161,250,000          
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset     (100,000) $ (900,000)          
3.00% Convertible senior notes due 2022 | Convertible debt                  
Financial assets and liabilities measured at fair value on recurring basis                  
Principal     150,000,000   150,000,000       $ 150,000,000.0
Interest rate ( as a percent )                 3.00%
Fair value of convertible notes     173,400,000   193,200,000        
Conversion price per share (in dollars per share) | $ / shares                 $ 56.34
1.50% Convertible senior notes due 2026 | Convertible debt                  
Financial assets and liabilities measured at fair value on recurring basis                  
Principal     $ 287,500,000   287,500,000   $ 287,500,000    
Interest rate ( as a percent )     1.50%       1.50%    
Fair value of convertible notes     $ 333,800,000   394,900,000        
Conversion price per share (in dollars per share) | $ / shares             $ 52.52    
Agilis                  
Financial assets and liabilities measured at fair value on recurring basis                  
Development milestone payments which the entity is obligated to pay     $ 40,000,000.0            
Agilis | Minimum                  
Financial assets and liabilities measured at fair value on recurring basis                  
Product sales (as a percent)     2.00%     2.00%      
Agilis | Maximum                  
Financial assets and liabilities measured at fair value on recurring basis                  
Product sales (as a percent)     6.00%     6.00%      
Development milestone payments which the entity is obligated to pay     $ 60,000,000.0            
Priority review voucher amount     535,000,000.0            
Net sales amount     150,000,000.0            
Recurring basis                  
Financial assets and liabilities measured at fair value on recurring basis                  
Fair value of convertible debt     $ 37,109,000   $ 29,252,000        
Common stock                  
Financial assets and liabilities measured at fair value on recurring basis                  
Shares purchased $ 100,000             $ 4,000,000.0  
Share price (in USD per share) | $ / shares $ 23.50             $ 3.10  
Development and Regulatory Milestone | Probability of Success | Weighted Average | Contingent Consideration Payable                  
Financial assets and liabilities measured at fair value on recurring basis                  
Rights Exchange settlement     42            
Development and Regulatory Milestone | Agilis | Measurement Input, Discount Rate | Weighted Average | Contingent Consideration Payable                  
Financial assets and liabilities measured at fair value on recurring basis                  
Rights Exchange settlement     3.2            
Net Sales Milestones and Royalties | Probability of Success | Weighted Average | Contingent Consideration Payable                  
Financial assets and liabilities measured at fair value on recurring basis                  
Rights Exchange settlement     48            
Net Sales Milestones and Royalties | Agilis | Measurement Input, Discount Rate | Contingent Consideration Payable                  
Financial assets and liabilities measured at fair value on recurring basis                  
Rights Exchange settlement     0.125